Breyanzi denied as non-formulary by Cigna?

Cigna's specific coverage criteria for breyanzi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Breyanzi: Non-Formulary

A non-formulary denial for Breyanzi (lisocabtagene maraleucel) means Cigna's drug benefit plan does not include Breyanzi on its standard formulary tier, or that Breyanzi requires a formulary exception before coverage can be extended. Because Breyanzi is a specialty CAR-T cell therapy administered in a hospital setting — not a self-administered retail drug — it may fall under a medical benefit rather than a pharmacy benefit, and the formulary structure that triggered the denial may not apply to your claim at all.

The first step in appealing a non-formulary denial for Breyanzi is clarifying which benefit category governs and whether Cigna's formulary exception process was correctly invoked.

## Why This Denial Is Appealable

For CAR-T therapies, insurers are generally required to cover FDA-approved treatments that have no therapeutic equivalent on formulary when a formulary exception is properly requested. A non-formulary denial without offering an equivalent alternative is particularly vulnerable on appeal. Additionally, if Breyanzi should be processed under the medical benefit (as a physician-administered drug) rather than the pharmacy benefit, the non-formulary classification may be a categorization error that the internal appeal process can correct quickly.

## Federal Appeal Framework

• Formulary exception request: File this simultaneously with or before the internal appeal — many plans require a formulary exception as a prerequisite and it can be processed faster.
• Internal appeal (ERISA §503 / ACA §2719): File within 180 days of denial. Standard decisions within 30–60 days; expedited within 72 hours.
• External review (ACA §2719): Available after final internal denial, generally within 4 months. An IRO determines whether the non-formulary classification was appropriate and whether an exception should have been granted.

## Documentation to Gather

• Prescribing oncologist's formulary exception letter — must state why Breyanzi is medically necessary and why no formulary alternative is clinically appropriate for your specific diagnosis and prior treatment history
• Benefit plan documents — obtain your Summary Plan Description and the pharmacy/specialty drug benefit section; confirm whether Breyanzi should be processed as a medical or pharmacy benefit
• FDA prescribing information for Breyanzi — confirms approved indication and administration route (hospital-based infusion), supporting classification as a medical-benefit drug
• Denial letter — note the exact basis (formulary tier, benefit category, or exception denial) to tailor your appeal
• Cigna's formulary exception criteria — obtain from the plan or Cigna's website; your appeal must address each listed exception ground

## Criteria-Mapping Structure

| Non-Formulary / Exception Criterion | Your Evidence | |---|---| | No formulary alternative clinically appropriate | [Oncologist's statement explaining why listed alternatives are not suitable for your diagnosis/history] | | Benefit category (medical vs. pharmacy) | [FDA label showing hospital-based infusion; argument for medical benefit processing] | | Medical necessity of Breyanzi specifically | [Diagnosis, prior therapy history, FDA indication match] | | Prescriber's clinical rationale | [Oncologist letter date and key statements] |

Many non-formulary denials for CAR-T therapies resolve at the formulary exception or internal appeal stage once the oncologist's letter clearly establishes that no formulary alternative can serve the same clinical purpose. If Cigna's denial was a benefit-category error, raising that in the internal appeal may resolve it without requiring external review.